Efficacy and safety of intravitreal anti-VEGF therapy in diabetic retinopathy: what we have learned and what should we learn further?

References

• Fong DS, Aiello L, Gardner TW, et al. Retinopathy in diabetes. Diabetes Care. 2004;27Suppl 1:S84–7. PubMed PMID: 14693935.
   PubMed Web of Science ®Google Scholar
• Antonetti DA, Klein R, Gardner TW. Diabetic retinopathy. N Engl J Med. 2012 Mar 29;366(13):1227–1239. PubMed PMID: 22455417.
   PubMed Web of Science ®Google Scholar
• Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. 2010 Jul 10;376(9735):124–136. PubMed PMID: 20580421.
   PubMed Web of Science ®Google Scholar
• Moss SE, Klein R, Klein BE. The 14-year incidence of visual loss in a diabetic population. Ophthalmology. 1998;105(6):998–1003. PubMed PMID: 9627648.
   PubMed Web of Science ®Google Scholar
• Stitt AW, Curtis TM, Chen M, et al. The progress in understanding and treatment of diabetic retinopathy. Prog Retin Eye Res. 2016;51:156–186. PubMed PMID: 26297071.
   PubMed Web of Science ®Google Scholar
• Calderon GD, Juarez OH, Hernandez GE, et al. Oxidative stress and diabetic retinopathy: development and treatment. Eye. 2017;318:1122–1130. PubMed PMID: 28452994; PubMed Central PMCID: PMCPMC5558229.
   PubMed Web of Science ®Google Scholar
• Stewart MW. Anti-vascular endothelial growth factor drug treatment of diabetic macular edema: the evolution continues. Curr Diabetes Rev. 2012 Jul 1;8(4):237–246. PubMed PMID: 22515701.
   PubMedGoogle Scholar
• Boyer DS, Hopkins JJ, Sorof J, et al. Anti-vascular endothelial growth factor therapy for diabetic macular edema. Ther Adv Endocrinol Metab. 2013;46:151–169. PubMed PMID: 24324855; PubMed Central PMCID: PMCPMC3855829.
   PubMedGoogle Scholar
• US Food and Drug Administration. Oncologic Drugs Advisory Committee Meeting Briefing Document ABP 215, a proposed biosimilar to Avastin 2017. [cited 2020 January 20]. Available from: https://www.fda.gov/media/106549/download
   Google Scholar
• Lode HE, Gjolberg TT, Foss S, et al. A new method for pharmaceutical compounding and storage of anti-VEGF biologics for intravitreal use in silicone oil-free prefilled plastic syringes. Sci Rep. 2019 Dec 2;9(1):18021. PubMed PMID: 31792234; PubMed Central PMCID: PMCPMC6888834.
   PubMedGoogle Scholar
• Retinopathy Clinical Research N D, Scott IU, and Edwards AR, et al. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. PubMed PMID: 17698196; PubMed Central PMCID: PMCPMC2245885, Ophthalmology. 2007;114(10):1860–1867.
   PubMed Web of Science ®Google Scholar
• Arevalo JF, Sanchez JG, Fromow-Guerra J, et al. Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema: results from the Pan-American Collaborative Retina Study Group (PACORES) at 12-month follow-up. Graefe’s archive for clinical and experimental ophthalmology. 2009 Jun;247(6):735–743. PubMed PMID: 19189118.
   PubMed Web of Science ®Google Scholar
• Rajendram R, Fraser-Bell S, Kaines A, et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Arch Ophtalmol. 2012;130(8):972–979. PubMed PMID: 22491395.
   PubMed Web of Science ®Google Scholar
• Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS report number 8 the diabetic retinopathy study research group. Ophthalmology. 1981 Jul;88(7):583–600. PubMed PMID: 7196564
   PubMed Web of Science ®Google Scholar
• Tonello M, Costa RA, Almeida FP, et al. Panretinal photocoagulation versus PRP plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy (IBeHi study). Acta Ophthalmol. 2008;864:385–389. PubMed PMID: 17995982.
   PubMed Web of Science ®Google Scholar
• Ernst BJ, Garcia-Aguirre G, Oliver SC, et al. Intravitreal bevacizumab versus panretinal photocoagulation for treatment-naive proliferative and severe nonproliferative diabetic retinopathy. Acta Ophthalmol. 2012;90(7):e573–4. PubMed PMID: 22405048.
   PubMedGoogle Scholar
• Arevalo JF, Lasave AF, Wu L, et al. INTRAVITREAL BEVACIZUMAB FOR PROLIFERATIVE DIABETIC RETINOPATHY: results From the Pan-American Collaborative Retina Study Group (PACORES) at 24 months of follow-up. PubMed PMID: 27429384, Retina. 2017;37(2):334–343.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. A 3-month study to assess the safety of ONS-5010 in subjects with visual impairment due to retinal disorders. [cited 2021 November 16]. [updated 2020 Apr 28; cited 2021 Nov 16]. Available from: https://clinicaltrials.gov/ct2/show/NCT04516278
   Google Scholar
• Fasih U, Shaikh N, Rahman A, et al. A one-year follow-up study of ocular and systemic complications of intravitreal injection of bevacizumab (Avastin). J Pak Med Assoc. 2013; 636: 707–710. PubMed PMID: 23901669.
   PubMed Web of Science ®Google Scholar
• Goldberg RA, Flynn HW Jr., Isom RF, et al. An outbreak of streptococcus endophthalmitis after intravitreal injection of bevacizumab. Am J Ophthalmol. 2012;1532:204–208 e1. PubMed PMID: 22264943; PubMed Central PMCID: PMCPMC3266537.
   PubMed Web of Science ®Google Scholar
• Tranos P, Gemenetzi M, Papandroudis A, et al. Progression of diabetic tractional retinal detachment following single injection of intravitreal Avastin. Eye. 2008;226:862. PubMed PMID: 18007674.
   PubMed Web of Science ®Google Scholar
• Afarid M, Sadegi Sarvestani A, Rahat F, et al. Intravitreal Injection of Bevacizumab: review of our previous Experience. Iran J Pharm Res. 2018;17(3):1093–1098. PubMed PMID: 30127831; PubMed Central PMCID: PMCPMC6094424.
   PubMed Web of Science ®Google Scholar
• Sangroongruangsri S, Chaikledkaew U, Kumluang S, et al. Real-world safety of intravitreal bevacizumab and ranibizumab treatments for retinal diseases in Thailand: a Prospective Observational Study. Clin Drug Investig. 2018;389:853–865. PubMed PMID: 30069864; PubMed Central PMCID: PMCPMC6153972.
   PubMed Web of Science ®Google Scholar
• Ferrara N, Damico L, Shams N, et al. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina. 2006;268:859–870. PubMed PMID: 17031284.
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Shah SM, Heier JS, et al. Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in diabetes (READ-2) study. PubMed PMID: 19700194, Ophthalmology. 2009;116(11):2175–81 e1.
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Shah SM, Khwaja AA, et al. Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology. 2010;11711:2146–2151. PubMed PMID: 20855114.
   PubMed Web of Science ®Google Scholar
• Do DV, Nguyen QD, Khwaja AA, et al. Ranibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatment. JAMA Ophthalmol. 2013;1312:139–145. PubMed PMID: 23544200.
   PubMed Web of Science ®Google Scholar
• Sepah YJ, Sadiq MA, Boyer D, et al. Twenty-four-month outcomes of the ranibizumab for edema of the macula in diabetes - protocol 3 with high dose (READ-3) Study. Ophthalmology. 2016;12312:2581–2587. PubMed PMID: 27707550.
   PubMed Web of Science ®Google Scholar
• Massin P, Bandello F, Garweg JG, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care. 2010;3311:2399–2405. PubMed PMID: 20980427; PubMed Central PMCID: PMCPMC2963502.
   PubMed Web of Science ®Google Scholar
• Retinopathy Clinical Research N D, Elman MJ, Aiello LP, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;1176:1064–1077 e35. PubMed PMID: 20427088; PubMed Central PMCID: PMCPMC2937272.
   PubMed Web of Science ®Google Scholar
• Elman MJ, Bressler NM, Qin H, et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2011;1184:609–614. PubMed PMID: 21459214; PubMed Central PMCID: PMCPMC3096445.
   PubMed Web of Science ®Google Scholar
• Retinopathy Clinical Research N D, Elman MJ, Qin H, et al. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. Ophthalmology. 2012;11911:2312–2318. PubMed PMID: 22999634; PubMed Central PMCID: PMCPMC3490003.
   PubMed Web of Science ®Google Scholar
• Elman MJ, Ayala A, Bressler NM, et al. Intravitreal Ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results. Ophthalmology. 2015;1222:375–381. PubMed PMID: 25439614; PubMed Central PMCID: PMCPMC4520307.
   PubMed Web of Science ®Google Scholar
• Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;1184:615–625. PubMed PMID: 21459215.
   PubMed Web of Science ®Google Scholar
• Ishibashi T, Li X, Koh A, et al. The REVEAL study: ranibizumab monotherapy or combined with laser versus laser monotherapy in asian patients with diabetic macular edema. Ophthalmology. 2015;1227:1402–1415. PubMed PMID: 25983216.
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. PubMed PMID: 22330964, Ophthalmology. 2012;119(4):789–801.
   PubMed Web of Science ®Google Scholar
• Brown DM, Nguyen QD, Marcus DM, et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology. 2013;120(10):2013–2022. PubMed PMID: 23706949.
   PubMed Web of Science ®Google Scholar
• Schmidt-Erfurth U, Lang GE, Holz FG, et al. Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study. Ophthalmology. 2014;1215:1045–1053. PubMed PMID: 24491642.
   PubMed Web of Science ®Google Scholar
• Pearce I, Banerjee S, Burton BJ, et al. Ranibizumab 0.5 mg for diabetic macular edema with bimonthly monitoring after a phase of initial treatment: 18-month, multicenter, phase IIIB RELIGHT Study. Ophthalmology. 2015;1229:1811–1819. PubMed PMID: 26150052.
   PubMed Web of Science ®Google Scholar
• Payne JF, Wykoff CC, Clark WL, et al. Randomized trial of treat and extend ranibizumab with and without navigated laser for diabetic macular edema: TREX-DME 1 Year Outcomes. Ophthalmology. 2017;1241:74–81. PubMed PMID: 27836430.
   PubMed Web of Science ®Google Scholar
• Ip MS, Domalpally A, Hopkins JJ, et al. Long-term effects of ranibizumab on diabetic retinopathy severity and progression. Arch Ophtalmol. 2012;130(9):1145–1152. PubMed PMID: 22965590.
   PubMed Web of Science ®Google Scholar
• Ip MS, Domalpally A, Sun JK, et al. Long-term effects of therapy with ranibizumab on diabetic retinopathy severity and baseline risk factors for worsening retinopathy. Ophthalmology. 2015;1222:367–374. PubMed PMID: 25439595.
   PubMed Web of Science ®Google Scholar
• Sadiq MA, Hassan M, Soliman MK, et al. Effects of two different doses of ranibizumab on diabetic retinopathy severity. Ophthalmol Retina. 2017;1(6):566–567. PubMed PMID: 31047459.
   PubMedGoogle Scholar
• Hassan M, Sadiq MA, Halim MS, et al. Short-Term effects of ranibizumab on diabetic retinopathy severity and progression. Ophthalmol Retina. 2018;27:749–751. PubMed PMID: 31047386.
   PubMedGoogle Scholar
• Bressler SB, Odia I, Glassman AR, et al. CHANGES IN DIABETIC RETINOPATHY SEVERITY WHEN TREATING DIABETIC MACULAR EDEMA WITH RANIBIZUMAB: DRCR.net Protocol I 5-Year Report. Retina. 2018;3810:1896–1904. PubMed PMID: 30234859; PubMed Central PMCID: PMCPMC6547828.
   PubMed Web of Science ®Google Scholar
• Research N, Gross JG, Glassman AR; Writing Committee for the Diabetic Retinopathy Clinical, et al. Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: a Randomized Clinical Trial. Jama. 2015 Nov 24;314(20):2137–2146. PubMed PMID: 26565927; PubMed Central PMCID: PMCPMC5567801.
   PubMed Web of Science ®Google Scholar
• Gross JG, Glassman AR, Liu D, et al. Five-year outcomes of panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial. JAMA Ophthalmol. 2018 Oct 1;136(10):1138–1148. PubMed PMID: 30043039; PubMed Central PMCID: PMCPMC6233839.
   PubMed Web of Science ®Google Scholar
• Li X, Dai H, Li X, et al. Efficacy and safety of ranibizumab 0.5 mg in Chinese patients with visual impairment due to diabetic macular edema: results from the 12-month REFINE study. Graefe’s archive for clinical and experimental ophthalmology. 2019 Mar;257(3):529–541. PubMed PMID: 30645696.
   PubMed Web of Science ®Google Scholar
• Yanagida Y, Ueta T. Systemic safety of ranibizumab for diabetic macular edema: meta-analysis of randomized trials. Retina. 2014;34(4):629–635. PubMed PMID: 24667549.
   PubMed Web of Science ®Google Scholar
• Balaratnasingam C, Dhrami-Gavazi E, McCann JT, et al. Aflibercept: a review of its use in the treatment of choroidal neovascularization due to age-related macular degeneration. Clin Ophthalmol. 2015;9:2355–2371. PubMed PMID: 26719668; PubMed Central PMCID: PMCPMC4689264.
   PubMed Web of Science ®Google Scholar
• Stewart MW, Rosenfeld PJ. Predicted biological activity of intravitreal VEGF Trap. Br J Ophthalmol. 2008;92(5):667–668. PubMed PMID: 18356264.
   PubMed Web of Science ®Google Scholar
• Sarwar S, Bakbak B, Sadiq MA, et al. Fusion Proteins: aflibercept (VEGF Trap-Eye). Dev Ophthalmol. 2016;55:282–294. PubMed PMID: 26501481.
   PubMedGoogle Scholar
• Do DV, Nguyen QD, Shah SM, et al. An exploratory study of the safety, tolerability and bioactivity of a single intravitreal injection of vascular endothelial growth factor Trap-Eye in patients with diabetic macular oedema. Br J Ophthalmol. 2009;932:144–149. PubMed PMID: 19174400.
   PubMed Web of Science ®Google Scholar
• Do DV, Schmidt-Erfurth U, Gonzalez VH, et al. The DA VINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema. Ophthalmology. 2011;1189:1819–1826. PubMed PMID: 21546089.
   PubMed Web of Science ®Google Scholar
• Do DV, Nguyen QD, Boyer D, et al. One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology. 2012;1198:1658–1665. PubMed PMID: 22537617.
   PubMed Web of Science ®Google Scholar
• Brown DM, Schmidt-Erfurth U, Do DV, et al. Intravitreal aflibercept for diabetic macular edema: 100-week results from the Vista and VIVID Studies. PubMed PMID: 26198808, Ophthalmology. 2015;122(10):2044–2052.
   PubMed Web of Science ®Google Scholar
• Heier JS, Korobelnik JF, Brown DM, et al. Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the Vista and VIVID Studies. Ophthalmology. 2016;12311:2376–2385. PubMed PMID: 27651226.
   PubMed Web of Science ®Google Scholar
• Baker CW, Glassman AR, Beaulieu WT, et al. Effect of initial management with aflibercept vs laser photocoagulation vs observation on vision loss among patients with diabetic macular edema involving the center of the macula and good visual acuity: a randomized clinical trial. Jama. 2019 May 21;321(19):1880–1894. PubMed PMID: 31037289; PubMed Central PMCID: PMCPMC6537845.
   PubMed Web of Science ®Google Scholar
• Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. PubMed PMID: 26935357; PubMed Central PMCID: PMCPMC4877252, Ophthalmology. 2016;123(6):1351–1359.
   PubMed Web of Science ®Google Scholar
• Glassman AR, Wells JA 3rd, Josic K, et al. Five-Year Outcomes after Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T Extension Study). Ophthalmology. 2020;1279:1201–1210. PubMed PMID: 32402554; PubMed Central PMCID: PMCPMC7483366.
   PubMed Web of Science ®Google Scholar
• Mitchell P, McAllister I, Larsen M, et al. Evaluating the impact of intravitreal aflibercept on diabetic retinopathy progression in the VIVID-DME and Vista-DME Studies. Ophthalmol Retina. 2018;210:988–996. PubMed PMID: 31047501.
   PubMedGoogle Scholar
• Bressler SB, Liu D, Glassman AR, et al. Change in diabetic retinopathy through 2 years: secondary analysis of a randomized clinical trial comparing Aflibercept, Bevacizumab, and Ranibizumab. JAMA Ophthalmol. 2017 Jun 1;135(6):558–568. PubMed PMID: 28448655; PubMed Central PMCID: PMCPMC5540030.
   PubMed Web of Science ®Google Scholar
• Sivaprasad S, Prevost AT, Vasconcelos JC, et al. Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial. Lancet. 2017 Jun 3;389(10085):2193–2203. PubMed PMID: 28494920.
   PubMed Web of Science ®Google Scholar
• Brown DM, Wykoff CC, Boyer D, et al. Evaluation of Intravitreal Aflibercept for the Treatment of Severe Nonproliferative Diabetic Retinopathy: results From the PANORAMA randomized clinical trial. JAMA Ophthalmol. 2021 Sep 1;139(9):946–955. PubMed PMID: 34351414; PubMed Central PMCID: PMCPMC8343518.
   PubMed Web of Science ®Google Scholar
• Ziemssen F, Schlottman PG, Lim JI, et al. Initiation of intravitreal aflibercept injection treatment in patients with diabetic macular edema: a review of VIVID-DME and Vista-DME data. Int J Retina Vitreous. 2016;2(1):16. PubMed PMID: 27847634; PubMed Central PMCID: PMCPMC5088462.
   PubMedGoogle Scholar
• Retinopathy Clinical Research N D, Wells JA, Glassman AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015 Mar 26;372(13):1193–1203. PubMed PMID: 25692915; PubMed Central PMCID: PMCPMC4422053.
   PubMed Web of Science ®Google Scholar
• Andrade GC, Dias JR, Maia A, et al. INTRAVITREAL INJECTIONS OF ZIV-AFLIBERCEPT FOR DIABETIC MACULAR EDEMA: a Pilot Study. Retina. 2016;369:1640–1645. PubMed PMID: 26991646.
   PubMed Web of Science ®Google Scholar
• Holz FG, Dugel PU, Weissgerber G, et al. Single-Chain antibody fragment VEGF Inhibitor RTH258 for neovascular age-related macular degeneration: a randomized controlled study. Ophthalmology. 2016;1235:1080–1089. PubMed PMID: 26906165.
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Das A, Do DV, et al. Brolucizumab: evolution through preclinical and clinical studies and the implications for the management of neovascular age-related macular degeneration. Ophthalmology. 2020 Jan 17;127(7):963–976. PubMed PMID: 32107066.
   PubMed Web of Science ®Google Scholar
• Dugel PU, Jaffe GJ, Sallstig P, et al. Brolucizumab versus aflibercept in participants with neovascular age-related macular degeneration: a randomized trial. Ophthalmology. 2017;1249:1296–1304. PubMed PMID: 28551167.
   PubMed Web of Science ®Google Scholar
• Dugel PU, Koh A, Ogura Y, et al. HAWK and HARRIER: phase 3, Multicenter, Randomized, Double-Masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2020;1271:72–84. PubMed PMID: 30986442.
   PubMed Web of Science ®Google Scholar
• Brown DM, Wolf S, Garweg J, et al. Brolucizumab for the treatment of visual impairment due to diabetic macular edema: 52-week results from the KITE and KESTREL studies. Invest Ophthalmol Vis Sci. 2021;62(8):1045.
   Web of Science ®Google Scholar
• Jain A, Chea S, Matsumiya W, et al. Severe vision loss secondary to retinal arteriolar occlusions after multiple intravitreal brolucizumab administrations. Am J Ophthalmol Case Rep. 2020;18:100687. PubMed PMID: 32280811; PubMed Central PMCID: PMCPMC7139151.
   PubMedGoogle Scholar
• Haug SJ, Hien DL, Uludag G, et al. Retinal arterial occlusive vasculitis following intravitreal brolucizumab administration. Am J Ophthalmol Case Rep. 2020;18:100680. PubMed PMID: 32258827; PubMed Central PMCID: PMCPMC7125319.
   PubMedGoogle Scholar
• Baumal CR, Spaide RF, Vajzovic L, et al. Retinal Vasculitis and Intraocular Inflammation after Intravitreal Injection of Brolucizumab. Ophthalmology. 2020;12710:1345–1359. PubMed PMID: 32344075.
   PubMed Web of Science ®Google Scholar
• American Society of Retina Specialists. Beavu update for ASRS members Published February 23, 2020 and 2020 Mar 30. Available from: https://www.asrs.org/clinical/clinical-updates
   Google Scholar
• Sharma A, Kumar N, Kuppermann BD, et al. Faricimab: expanding horizon beyond VEGF. Eye. 2020;345:802–804. PubMed PMID: 31695160; PubMed Central PMCID: PMCPMC7182558.
   PubMed Web of Science ®Google Scholar
• Wykoff CC, Abreu F, Adamis AP, et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet. 2022 Jan 21;399(10326):741–755. PubMed PMID: 35085503.
   PubMed Web of Science ®Google Scholar
• Sahni J, Patel SS, Dugel PU, et al. Simultaneous inhibition of angiopoietin-2 and vascular endothelial growth factor-a with faricimab in diabetic macular edema: BOULEVARD Phase 2 randomized trial. Ophthalmology. 2019;1268:1155–1170. PubMed PMID: 30905643.
   PubMed Web of Science ®Google Scholar
• NJ PSS, Qudrat A, Do DV, et al. Phase 1 first-in-human study of KSI-301: a novel anti-VEGF antibody biopolymer conjugate with extended durability. Invest Ophthalmol Vis Sci. 2019;60:3670.
   Web of Science ®Google Scholar
• Jd PSS, Miller B, Ehrlich JS, et al. Updated results of phase 1b Study of KSI-301, an Anti-VEGF antibody biopolymer conjugate with extended durability, in wAMD, DME, and RVO. Invest Ophthalmol Vis Sci. 2020;61(7):4286.
   Google Scholar
• ClinicalTrials.gov. A study to evaluate the efficacy and safety of ksi-301, an anti-vegf antibody biopolymer conjugate, versus aflibercept in patients with Neovascular (Wet) age-related macular degeneration (DAZZLE). [updated 2020 Nov 19; cited 2020 Nov 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT04049266
   Google Scholar
• Bressler SB, Ayala AR, Bressler NM, et al. Persistent macular thickening after ranibizumab treatment for diabetic macular edema with vision impairment. JAMA Ophthalmol. 2016;1343:278–285. PubMed PMID: 26746868; PubMed Central PMCID: PMCPMC4786449.
   PubMed Web of Science ®Google Scholar
• Pieramici DJ, Wang PW, Ding B, et al. Visual and anatomic outcomes in patients with diabetic macular edema with limited initial anatomic response to ranibizumab in RIDE and RISE. Ophthalmology. 2016;1236:1345–1350. PubMed PMID: 26992841.
   PubMed Web of Science ®Google Scholar
• Bressler NM, Beaulieu WT, Glassman AR, et al. Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: a Secondary Analysis of a Randomized Clinical Trial. JAMA Ophthalmol. 2018 Mar 1;136(3):257–269. PubMed PMID: 29392288; PubMed Central PMCID: PMCPMC5885906.
   PubMed Web of Science ®Google Scholar
• Maturi RK, Glassman AR, Liu D, et al. Effect of adding dexamethasone to continued ranibizumab treatment in patients with persistent diabetic macular edema: a DRCR network phase 2 randomized clinical trial. JAMA Ophthalmol. 2018 Jan 1;136(1):29–38. PubMed PMID: 29127949; PubMed Central PMCID: PMCPMC5833605.
   PubMed Web of Science ®Google Scholar
• Binder S. Loss of reactivity in intravitreal anti-VEGF therapy: tachyphylaxis or tolerance? Br J Ophthalmol. 2012;96(1):1–2. PubMed PMID: 22157632.
   PubMed Web of Science ®Google Scholar
• Wallsh JO, Gallemore RP. Anti-VEGF-resistant retinal diseases: a review of the latest treatment options. Cells. 2021 Apr 29;10(5):1049. PubMed PMID: 33946803; PubMed Central PMCID: PMCPMC8145407.
   PubMed Web of Science ®Google Scholar
• Klein KA, Cleary TS, Reichel E. Effect of intravitreal aflibercept on recalcitrant diabetic macular edema. Int J Retina Vitreous. 2017;3(1):16. PubMed PMID: 28373914; PubMed Central PMCID: PMCPMC5376679.
   PubMedGoogle Scholar
• Salimi A, Vila N, Modabber M, et al. One-year outcomes of Aflibercept for refractory diabetic macular edema in Bevacizumab nonresponders. Indian J Ophthalmol. 2021;692:360–367. PubMed PMID: 33463593; PubMed Central PMCID: PMCPMC7933844.
   PubMed Web of Science ®Google Scholar
• Laiginhas R, Silva MI, Rosas V, et al. Aflibercept in diabetic macular edema refractory to previous bevacizumab: outcomes and predictors of success. Graefe’s archive for clinical and experimental ophthalmology. 2018 Jan;256(1):83–89. PubMed PMID: 29082448.
   PubMed Web of Science ®Google Scholar
• Liu Y, Cheng J, Gao Y, et al. Efficacy of switching therapy to aflibercept for patients with persistent diabetic macular edema: a systematic review and meta-analysis. Ann Transl Med. 2020;86:382. PubMed PMID: 32355826; PubMed Central PMCID: PMCPMC7186737.
   PubMed Web of Science ®Google Scholar
• Sorour OA, Liu K, Mehta N, et al. Visual and anatomic outcomes of sustained single agent anti-VEGF treatment versus double anti-VEGF switching in the treatment of persistent diabetic macular edema. Int J Retina Vitreous. 2020;6(1):17. PubMed PMID: 32523776; PubMed Central PMCID: PMCPMC7278067.
   PubMedGoogle Scholar
• Arevalo JF, Liu TYA. Pan-American Collaborative Retina Study G. Intravitreal bevacizumab in diabetic retinopathy. recommendations from the pan-American collaborative retina study group (PACORES): the 2016 Knobloch Lecture. Asia Pac J Ophthalmol (Phila). 2018;7(1):36–39. PubMed PMID: 29280367.
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004 Jun 3;350(23):2335–2342. PubMed PMID: 15175435.
   PubMed Web of Science ®Google Scholar
• Loupakis F, Cremolini C, Masi G, et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med. 2014 Oct 23;371(17):1609–1618. PubMed PMID: 25337750.
   PubMed Web of Science ®Google Scholar
• Edington M, Connolly J, Chong NV. Pharmacokinetics of intravitreal anti-VEGF drugs in vitrectomized versus non-vitrectomized eyes. Expert Opin Drug Metab Toxicol. 2017;13(12):1217–1224. PubMed PMID: 29134820.
   PubMed Web of Science ®Google Scholar
• Yanyali A, Aytug B, Horozoglu F, et al. Bevacizumab (Avastin) for diabetic macular edema in previously vitrectomized eyes. Am J Ophthalmol. 2007;1441:124–126. PubMed PMID: 17601433.
   PubMed Web of Science ®Google Scholar
• Mehta S, Blinder KJ, Shah GK, et al. Intravitreal bevacizumab for the treatment of refractory diabetic macular edema. Ophthalmic Surg Lasers Imaging. 2010;413:323–329. PubMed PMID: 20507016.
   PubMedGoogle Scholar
• Laugesen CS, Ostri C, Brynskov T, et al. Intravitreal ranibizumab for diabetic macular oedema in previously vitrectomized eyes. Acta Ophthalmol. 2017;951:28–32. PubMed PMID: 27473397.
   PubMed Web of Science ®Google Scholar
• Koyanagi Y, Yoshida S, Kobayashi Y, et al. Comparison of the effectiveness of intravitreal ranibizumab for diabetic macular edema in vitrectomized and nonvitrectomized eyes. Ophthalmologica. 2016;236(2):67–73. PubMed PMID: 27362944.
   PubMed Web of Science ®Google Scholar
• Do DV, Rhoades W, Nguyen QD. pharmacokinetic study of intravitreal aflibercept in humans with neovascular age-related macular degeneration. Retina. 2020;40(4):643–647. PubMed PMID: 31145389.
   PubMed Web of Science ®Google Scholar
• Krohne TU, Eter N, Holz FG, et al. Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am J Ophthalmol. 2008;1464:508–512. PubMed PMID: 18635152.
   PubMed Web of Science ®Google Scholar
• Krohne TU, Liu Z, Holz FG, et al. Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans. Am J Ophthalmol. 2012;1544:682–686 e2. PubMed PMID: 22818800.
   PubMed Web of Science ®Google Scholar
• Bressler SB, Melia M, Glassman AR, et al. Ranibizumab plus prompt or deferred laser for diabetic macular edema in eyes with vitrectomy before anti-vascular endothelial growth factor therapy. Retina. 2015;3512:2516–2528. PubMed PMID: 26035510; PubMed Central PMCID: PMCPMC4658280.
   PubMed Web of Science ®Google Scholar
• Tran THC, Erginay A, Verdun S, et al. One-year outcome of aflibercept intravitreal injection in vitrectomized eyes with diabetic macular edema. Clin Ophthalmol. 2021;15:1971–1978. PubMed PMID: 34007150; PubMed Central PMCID: PMCPMC8123959.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. A pharmacokinetic study: ranibizumab, aflibercept and the effect of vitrectomy (VITCLEAR). updated 2021 Apr 30; cited 2022 Feb 11].
   Google Scholar
• Sharma A, Kumar N, Parachuri N, et al. Faricimab: two in the bush is proving better than one in the hand? Ocul Immunol Inflamm. 2021;9:1–3. PubMed PMID: 34242102.
   Google Scholar
• Cai J, Kehoe O, Smith GM, et al. The angiopoietin/Tie-2 system regulates pericyte survival and recruitment in diabetic retinopathy. Invest Ophthalmol Vis Sci. 2008;495:2163–2171. PubMed PMID: 18436850.
   PubMed Web of Science ®Google Scholar